14May 2021
Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication

Antifibrotic drugs for pulmonary sarcoidosis: A treatment in search of an indication

The most common causes of disability and death from sarcoidosis are directly or indirectly related to complications of fibrotic lung disease.1 Fibrosis develops in up to 20% of pulmonary sarcoidosis patients2,3 and may result in end-stage parenchymal lung disease.4 Fibrotic pulmonary sarcoidosis is associated with distortion of airways leading to airflow obstruction, bronchiectasis, and increased episodes of clinical worsening that are often...

  • #pulmonology

Like

Save

Share